Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor ...

Esophageal squamous cell carcinoma (ESCC) is a deadly cancer with particularly high prevalence in East Asia. While ...

"Our whole lives changed at that moment. I cried and felt the floor drop from below us," Jodi McNamara told Newsweek.

The 14-gene assay identified patients with molecular high risk who benefitted from adjuvant chemotherapy. Use of the assay to determine eligibility for adjuvant therapy in stage IA–IIA non-squamous ...

Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma prior to surgery. ClinicalTrials.gov. Updated October 26, 2022.

The receptor for the complement component C5a may be a useful therapeutic target for cases of cutaneous squamous cell carcinoma (cSCC), according to a new report. 1 The study, published in the ...

Traws Pharma published key clinical efficacy data for rigosertib in patients with RDEB-associated squamous cell carcinoma. What is rigosertib being evaluated for?

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

In 2023, we reported on two patients with metastatic head and neck squamous cell carcinoma (HNSCC) with different responses to immune checkpoint inhibitor (ICI)-based treatment.

Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE ...

The stages of squamous cell carcinoma range from 0–4. Stage 0 is a precancerous stage, and stage 4 is advanced or metastatic cancer.

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.